<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013415</url>
  </required_header>
  <id_info>
    <org_study_id>WU #8829-99</org_study_id>
    <nct_id>NCT01013415</nct_id>
  </id_info>
  <brief_title>CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients</brief_title>
  <acronym>CD4-ZETA</acronym>
  <official_title>A Phase I/II Study Of the Safety, Survival, and Trafficking of Autologous CD4-ZETA Gene-Modified T Cells With and Without Extension Interleukin-2 in HIV Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the safety and activity of an experimental anti-HIV
      treatment using autologous CD4-zeta gene-changed T cells and/or IL-2 (recombinant
      interleukin2). The treatments that the investigators are studying try to improve the immune
      system by changing some of your T cells so they can find and destroy HIV infected cells (HIV
      is usually able to hide from your T cells). In this study, the investigators are also trying
      to find out if giving you more IL-2 at the same time as gene changed T cells will help the T
      cells to live longer or fight HIV better.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety/tolerability/feasibility of administering autologous CD4-zeta gene modified T cells IV in a setting of highly active antiretroviral therapy (HAART) w &amp; w/o IL-2 at a dose of ~1.2 M IU/m2 SQ daily for 56 days</measure>
    <time_frame>Day 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the effect of daily subcutaneous IL-2 on the persistence and trafficking of CD4-zeta gene modified T cells in the circulation and lymphoid (rectal) tissue</measure>
    <time_frame>End of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the effect of CD4-zeta infusions with and without IL-2 on viral load (plasma HIV-1 RNA, tissue HIV-1 RNA, and frequency of latent replication-competent HIV-1 in PBMC).</measure>
    <time_frame>End of Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the enhancing effect of CD4-zeta infusions on lymphocyte function</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine effect of IL-2 on CD4 naive and memory lymphocytes</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>HIV-1 Infections</condition>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HAART, IL-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HAART, T cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HAART, IL-2, T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAART</intervention_name>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_label>ARM 3</arm_group_label>
    <other_name>ARM 1, ARM 2, ARM 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T cells</intervention_name>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_label>ARM 3</arm_group_label>
    <other_name>ARM 2, ARM 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DOD beneficiary with HIV-1 infection

          -  Greater than or equal to 200 CD4 cells/mm3

          -  Undetectable viral load, for at least the previous 8 weeks

          -  Stable anti-retroviral regimen for greater than or equal to 8 weeks

          -  Venous access sufficient for apheresis

          -  Karnofsky performance &gt; 80%

        Exclusion Criteria:

          -  Inadequate organ function

          -  Lifetime history of CD4 count less than 200 cells/mm3 on 2 consecutive measurements
             over at least an 8 week period

          -  Any previous history of gene therapy

          -  Recent IL-2 therapy or other treatment with an investigational agent

          -  Pregnancy

          -  some medications (hydroxyurea, corticosteroids and other immunosuppressants,
             chemotherapy, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Aronson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2009</study_first_submitted>
  <study_first_submitted_qc>November 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

